Cardiovascular and bleeding risks in acute myocardial infarction newly treated with ticagrelor vs. Clopidogrel in Taiwan

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: There are few data on ticagrelor in Asian patients. This study evaluated clinical outcomes with ticagrelor and clopidogrel in Taiwanese patients with acute myocardial infarction (AMI). Methods and Results: We used the Taiwan National Health Insurance Research Database to identify 27,339 AMI patients aged ≥18 years between January 2012 and December 2014, and only patients who survived greater than or equal to 30 days after AMI and took dual antiplatelet therapy were included. Cohorts of ticagrelor and clopidogrel were matched 1:8, based on propensity score matching, to balance baseline covariates. The primary efficacy endpoints were death from any cause, AMI, or stroke. The safety endpoints consisted of major gastrointestinal bleeding or intracerebral hemorrhage. Following propensity matching, the primary efficacy endpoint rate was 22% lower in the ticagrelor group than in the clopidogrel group (10.6% and 16.2%, respectively; adjusted HR, 0.779; 95% CI: 0.684–0.887). The safety endpoint rate was similar between the ticagrelor and clopidogrel groups (3.2% and 4.1% respectively; adjusted HR, 0.731; 95% CI: 0.522–1.026). Conclusions: In real-world AMI Taiwanese patients, ticagrelor seemed to offer better anti-ischemic protection than clopidogrel, without an increase in the rate of major bleeding. A large-scale randomized trial is needed to assess the efficacy and safety of ticagrelor in East Asian AMI patients.

Original languageEnglish
Pages (from-to)747-756
Number of pages10
JournalCirculation Journal
Volume82
Issue number3
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

clopidogrel
Taiwan
Myocardial Infarction
Hemorrhage
Safety
Propensity Score
Gastrointestinal Hemorrhage
Cerebral Hemorrhage
National Health Programs
Ticagrelor
Cause of Death

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{a6155872bbfe426a9ea1f44ac4f137b9,
title = "Cardiovascular and bleeding risks in acute myocardial infarction newly treated with ticagrelor vs. Clopidogrel in Taiwan",
abstract = "Background: There are few data on ticagrelor in Asian patients. This study evaluated clinical outcomes with ticagrelor and clopidogrel in Taiwanese patients with acute myocardial infarction (AMI). Methods and Results: We used the Taiwan National Health Insurance Research Database to identify 27,339 AMI patients aged ≥18 years between January 2012 and December 2014, and only patients who survived greater than or equal to 30 days after AMI and took dual antiplatelet therapy were included. Cohorts of ticagrelor and clopidogrel were matched 1:8, based on propensity score matching, to balance baseline covariates. The primary efficacy endpoints were death from any cause, AMI, or stroke. The safety endpoints consisted of major gastrointestinal bleeding or intracerebral hemorrhage. Following propensity matching, the primary efficacy endpoint rate was 22{\%} lower in the ticagrelor group than in the clopidogrel group (10.6{\%} and 16.2{\%}, respectively; adjusted HR, 0.779; 95{\%} CI: 0.684–0.887). The safety endpoint rate was similar between the ticagrelor and clopidogrel groups (3.2{\%} and 4.1{\%} respectively; adjusted HR, 0.731; 95{\%} CI: 0.522–1.026). Conclusions: In real-world AMI Taiwanese patients, ticagrelor seemed to offer better anti-ischemic protection than clopidogrel, without an increase in the rate of major bleeding. A large-scale randomized trial is needed to assess the efficacy and safety of ticagrelor in East Asian AMI patients.",
author = "Lee, {Cheng Han} and Cheng, {Ching Lan} and {Kao Yang}, {Yea Huei} and Chao, {Ting Hsing} and Chen, {Ju Yi} and Li, {Yi Heng}",
year = "2018",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-17-0632",
language = "English",
volume = "82",
pages = "747--756",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "3",

}

TY - JOUR

T1 - Cardiovascular and bleeding risks in acute myocardial infarction newly treated with ticagrelor vs. Clopidogrel in Taiwan

AU - Lee, Cheng Han

AU - Cheng, Ching Lan

AU - Kao Yang, Yea Huei

AU - Chao, Ting Hsing

AU - Chen, Ju Yi

AU - Li, Yi Heng

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: There are few data on ticagrelor in Asian patients. This study evaluated clinical outcomes with ticagrelor and clopidogrel in Taiwanese patients with acute myocardial infarction (AMI). Methods and Results: We used the Taiwan National Health Insurance Research Database to identify 27,339 AMI patients aged ≥18 years between January 2012 and December 2014, and only patients who survived greater than or equal to 30 days after AMI and took dual antiplatelet therapy were included. Cohorts of ticagrelor and clopidogrel were matched 1:8, based on propensity score matching, to balance baseline covariates. The primary efficacy endpoints were death from any cause, AMI, or stroke. The safety endpoints consisted of major gastrointestinal bleeding or intracerebral hemorrhage. Following propensity matching, the primary efficacy endpoint rate was 22% lower in the ticagrelor group than in the clopidogrel group (10.6% and 16.2%, respectively; adjusted HR, 0.779; 95% CI: 0.684–0.887). The safety endpoint rate was similar between the ticagrelor and clopidogrel groups (3.2% and 4.1% respectively; adjusted HR, 0.731; 95% CI: 0.522–1.026). Conclusions: In real-world AMI Taiwanese patients, ticagrelor seemed to offer better anti-ischemic protection than clopidogrel, without an increase in the rate of major bleeding. A large-scale randomized trial is needed to assess the efficacy and safety of ticagrelor in East Asian AMI patients.

AB - Background: There are few data on ticagrelor in Asian patients. This study evaluated clinical outcomes with ticagrelor and clopidogrel in Taiwanese patients with acute myocardial infarction (AMI). Methods and Results: We used the Taiwan National Health Insurance Research Database to identify 27,339 AMI patients aged ≥18 years between January 2012 and December 2014, and only patients who survived greater than or equal to 30 days after AMI and took dual antiplatelet therapy were included. Cohorts of ticagrelor and clopidogrel were matched 1:8, based on propensity score matching, to balance baseline covariates. The primary efficacy endpoints were death from any cause, AMI, or stroke. The safety endpoints consisted of major gastrointestinal bleeding or intracerebral hemorrhage. Following propensity matching, the primary efficacy endpoint rate was 22% lower in the ticagrelor group than in the clopidogrel group (10.6% and 16.2%, respectively; adjusted HR, 0.779; 95% CI: 0.684–0.887). The safety endpoint rate was similar between the ticagrelor and clopidogrel groups (3.2% and 4.1% respectively; adjusted HR, 0.731; 95% CI: 0.522–1.026). Conclusions: In real-world AMI Taiwanese patients, ticagrelor seemed to offer better anti-ischemic protection than clopidogrel, without an increase in the rate of major bleeding. A large-scale randomized trial is needed to assess the efficacy and safety of ticagrelor in East Asian AMI patients.

UR - http://www.scopus.com/inward/record.url?scp=85042464887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042464887&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-17-0632

DO - 10.1253/circj.CJ-17-0632

M3 - Article

C2 - 29081474

AN - SCOPUS:85042464887

VL - 82

SP - 747

EP - 756

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 3

ER -